GLP-1 Injections
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
(3)Capsule
(4)Injection
(5)Liquid Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-3-094
GLP-1 CAS 87805-34-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
Eli Lilly GLP1R/GIPR dual agonist new drug has been approved for multiple clinical trials in China
On November 21, 2025, according to the CDE official website, multiple indications for Eli Lilly Breniptide injection have been approved for clinical use, including: 1) treating moderate to severe asthma in adults; 2) Used as an adjuvant therapy for the prevention of adult schizophrenia; 3) Used as an adjuvant therapy for preventing recurrence of adult bipolar disorder (BD).
Brenipatide is a GLP1R/GlIPR dual agonist and also the second GLP-1/GIP dual target new drug from Eli Lilly and Company, following Telopotide. Tilpotide sold $24.8 billion in the first three quarters of 2025, a year-on-year increase of 125%, making it one of the highest selling drugs in the world.
Shiyao Group's double stranded small interfering RNA drug SYH2061 injection has been approved for clinical use in the United States
On November 24, 2025, Shiyao Group (1093. HK) announced that its independently developed Class 1 chemical new drug, a double stranded small interfering RNA (siRNA) drug (SYH2061 injection), has been approved by the US Food and Drug Administration (FDA) for clinical trials in the United States. The product has also been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China in October 2025.
This product is an siRNA drug that achieves hepatic fat delivery by coupling acetylgalactosamine (GalNAo). It is delivered subcutaneously to complement protein C5 (C5), effectively reducing C5 levels. By optimizing the sequence and chemical modification strategy, this product can achieve a more durable gene silencing effect. It is the first domestically developed siRNA drug with ultra long efficacy to reduce C5 levels that has entered clinical trials. It is suitable for the treatment of IgA nephropathy and other complement mediated related diseases.
Preclinical studies have shown that this product outperforms similar siRNA products in terms of drug activity and sustained efficacy, demonstrating differentiated advantages such as long-lasting drug effects, good safety, and high patient compliance. It has high clinical development value.
Two Phase III studies on the treatment of early Alzheimer's disease with oral semaglutide have failed
On November 24, 2025, Novo Nordisk announced the main analysis results of a two-year clinical trial of oral semaglutide for early-stage symptomatic Alzheimer's disease using evoke and evoke+.
product key technologies
Both trials were randomized, double-blind, and recruited 3808 adults to evaluate the efficacy and safety of adding oral semaglutide to standard treatment compared to placebo. The decision to explore the indications of smeglutide for Alzheimer's disease is based on real world evidence studies, preclinical models and post hoc analysis of diabetes and obesity trials.
The evoke and evoke+trials failed to confirm that semaglutide is superior to placebo in slowing down the progression of Alzheimer's disease. This evaluation is mainly based on changes in the total score of the Clinical Dementia Rating Scale relative to baseline. Although semaglutide treatment improved Alzheimer's disease-related biomarkers in both trials, this did not translate into delayed disease progression.
Arrowhead receives $2 billion payment from Sarepta, breakthrough in ARO-DM1 clinical trial
On November 24, 2025, Arrowhead Pharmaceuticals announced that it had received a milestone payment of $200 million from Sarepta Therapeutics, triggered after Arrowhead completed the second development milestone event in a Phase 1/2 clinical study of ARO-DM1 (also known as SRP-1003). According to the license and cooperation agreement signed with Sarepta, Arrowhead expects to receive the payment within 60 days.
ARO-DM1 is an siRNA therapy targeting skeletal muscle developed by Arrowhead Pharmaceuticals using its proprietary TRiMm platform, aimed at reducing the expression of the dystrophin kinase (DMPK) gene through RNA interference (RNAj) mechanism for the treatment of type 1 muscular dystrophy (DM1).